AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $198.07M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.79M
Average 0.29M
Returns on capital
AN2 Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-66.3%
avg -207.9%
ROIC
-71.6%
avg -156.6%
ROA
-56.8%
avg -163.8%
Analysis
ROA is currently the strongest return metric at -56.8% versus its period average of -163.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | USD 943.31K | 58 | — | — |
Cameron Trenor | Chief Medical Officer | USD 688.2K | — | — | — |
Lucy O. Day | CFO, & Principal Financial Officer | USD 633.58K | 66 | — | — |
Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | USD 630K | 47 | — | — |
Joseph S. Zakrzewski | Co-Founder & Independent Director | USD 51.5K | 64 | 0 | <0.01% |
Michael R. K. Alley | Co-founder & Head of Biology | — | — | — | — |
Sanjay Chanda | Chief Development Officer | — | 60 | 0 | <0.01% |
Vince Hernandez | Head of Research | — | — | — | — |
Sarah Williams | Vice President of Controller & Principal Accounting Officer | — | 38 | — | — |
George Harrison Talbot FACP | Co-Founder & Senior Clinical Advisor | — | 78 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$11,601.94
Sells
21
$406,138.10
Net Transaction Value
−$394,536.16
Net selling
Most Active
Readnour Robin Shane
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | Eizen Joshua M Direct | Sell | $11.9K$11,925.72 |
| Sep 9, 26Sep 9, 2026 | Readnour Robin Shane Indirect | Sell | $3.2K$3,150.71 |
| Sep 9, 26Sep 9, 2026 | Readnour Robin Shane Indirect | Sell | $3.5K$3,524.22 |
| Sep 8, 26Sep 8, 2026 | Readnour Robin Shane Indirect | Sell | $31.9K$31,860.88 |
| Sep 8, 26Sep 8, 2026 | Readnour Robin Shane Indirect | Sell | $28.4K$28,436.47 |
| Sep 3, 26Sep 3, 2026 | Readnour Robin Shane Indirect | Sell | $17.5K$17,462.81 |
| Sep 3, 26Sep 3, 2026 | Readnour Robin Shane Indirect | Sell | $19.6K$19,562.97 |
| Sep 1, 26Sep 1, 2026 | Williams Sarah Joanne Direct | Sell | $1.5K$1,504.16 |
| Sep 1, 26Sep 1, 2026 | FitzPatrick Margaret M Direct | Buy | $11.6K$11,601.94 |
| Aug 17, 26Aug 17, 2026 | Readnour Robin Shane Indirect | Sell | $112.4K$112,389.39 |
1–10 of 22
Summary
Insiders reported 1 buys worth $11,601.94 and 21 sells worth $406,138.10 over the last 12 months. That adds up to net selling of $394,536.16. Readnour Robin Shane was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does AN2 Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ANTX's management, answered from reported figures.
Who manages ANTX?
AN2 Therapeutics, Inc. (ANTX) lists 10 active executives. The top listed executive is Cameron Trenor, Chief Medical Officer.
Are ANTX insiders buying or selling?
Recent insider activity shows net selling of $16.32M.
Continue the stock analysis
Jump to another research area for this company.